REG - ReNeuron Group plc - Director Share Purchases <Origin Href="QuoteRef">RQE.L</Origin>

ReNeuronAnnouncement

30/01/2015 07:11

RNS Number : 5400D
ReNeuron Group plc
30 January 2015
30 January 2015 
AIM: RENE
ReNeuron Group plc
("ReNeuron" or "the Company")
 Director Share Purchases
Guildford, UK, 30 January 2015:ReNeuron Group plc (AIM: RENE), a leading UK-based stem cell therapy company, was informed on 29 January 2015 that two of its Directors acquired ordinary shares of 1p each ("Ordinary Shares") as follows:




Interest after purchase
Director 
Title
Number of Ordinary Shares acquired on
29 January 2015
Price
per share 
Number of Ordinary Shares
% of total
issued share capital
OlavHelleb
Chief Executive Officer
322,778
3.1p
322,778
0.02%
Michael Hunt
Chief Financial Officer
161,556
3.1p
1,508,471
0.08%
The issued share capital of the Company is 1,788,827,700 1p ordinary shares.
Enquiries:
ReNeuron
+44 (0) 1483 302560
Olav Helleb, Chief Executive Officer
Michael Hunt, Chief Financial Officer
Buchanan
+44 (0) 20 7466 5000
Mark Court, Sophie Cowles, Stephanie Watson
Cenkos Securities
+44 (0) 20 7397 8900
Stephen Keys, Dr Christopher Golden (NOMAD and Broker)
Andy Roberts (Sales)
About ReNeuron
ReNeuron is a leading, clinical-stage cell therapy development business. Based in the UK, its primary objective is the development of novel cell-based therapies targeting areas of significant unmet or poorly met medical need.
ReNeuron has used its unique stem cell technologies to develop cell-based therapies for significant disease conditions where the cells can be readily administered "off-the-shelf" to any eligible patient without the need for additional immunosuppressive drug treatments. The Company's therapeutic candidates for stroke disability and critical limb ischaemia are in clinical development and its cell-based treatment for blindness-causing diseases of the retina is currently in pre-clinical development.
ReNeuron is also advancing a proprietary platform technology to exploit nanoparticles (exosomes) secreted by stem cells as potential new drug candidates targeting indications in tissue repair, fibrosis and cancer.
ReNeuron's shares are traded on the London AIM market under the symbol RENE.L. Further information on ReNeuron and its products can be found at www.reneuron.com.

This information is provided by RNS
The company news service from the London Stock Exchange
  END
RDSPKCDBABKDDDB